Login / Signup

Tocilizumab Induces Rapid, Sustained Improvement of Inflammatory Markers in COVID-19, With Clinical Improvement in Most Patients.

Scott J MorinChinmay T JaniArashdeep RupalHarpreet SinghDaniel BourqueRobert C Colgrove
Published in: American journal of therapeutics (2021)
Keyphrases
  • end stage renal disease
  • coronavirus disease
  • ejection fraction
  • sars cov
  • newly diagnosed
  • rheumatoid arthritis
  • systemic lupus erythematosus